Back to Liraglutide research
liraglutide glp 1 agonist preclinical animal n preclinical 2026-04-24 PubMed

Neuronal Cav3.1 Channel Senses Leucine to Drive Satiety and Weight Loss

Cav3.1 is a neuronal leucine sensor that mediates satiety and weight loss in response to dietary protein.

Background

Dietary protein is widely recognized for its ability to promote satiety and facilitate weight loss, yet the precise mechanisms by which appetite-regulating neurons detect dietary protein remain poorly understood. This study aimed to uncover the specific neuronal sensor responsible for mediating the appetite- and weight-suppressive effects of dietary protein.

Results

The study found that Cacna1g, encoding Cav3.1, is highly enriched in hypothalamic leucine-sensing neurons and is crucial for their response to leucine. Pharmacological inhibition of Cav3.1 was shown to blunt leucine-induced activation of POMC neurons in vitro, which subsequently suppressed the anorectic response to hypothalamic leucine in vivo. Mechanistically, leucine was found to directly bind to a hydrophobic pocket within Cav3.1, which lowers its threshold for voltage-dependent activation. Genetic deletion of Cacna1g specifically in POMC neurons completely abolished the appetite- and weight-suppressive effects observed with high-protein feeding, highlighting Cav3.1's indispensable role. Furthermore, pharmacological activation of mediobasal hypothalamic Cav3.1 in diet-induced obese mice promoted significant weight loss and potentiated responses to other anorectic agents, including liraglutide.

Why It Matters

These findings establish hypothalamic Cav3.1 as a crucial neuronal leucine sensor, providing a novel and fundamental understanding of how dietary protein influences satiety and body weight. This discovery suggests that targeting Cav3.1 could be a highly tractable strategy for developing innovative anti-obesity therapies. Future research should focus on identifying specific and selective Cav3.1 activators suitable for human use and exploring their efficacy in Phase II clinical studies.


liraglutide glp 1 agonist
Source: pubmed:42025169 · Ingested 2026-04-24 · Digest: gemini-2.5-flash